Caxton Associates LP Coherus Bio Sciences, Inc. Transaction History

Caxton Associates LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$3.74 - $5.45 $334,629 - $487,627	89,473 New	89,473 $334,000
Q1 2023 May 15, 2023	BUY	$5.89 - $10.52 $660,775 - $1.18 Million	112,186 New	112,186 $767,000
Q2 2022 Aug 15, 2022	BUY	$5.86 - $13.23 $75,547 - $170,561	12,892 New	12,892 $93,000
Q2 2020 Aug 14, 2020	SELL	$14.43 - $19.16 $171,096 - $227,180	-11,857 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$11.67 - $22.53 $81,690 - $157,710	-7,000 Reduced 37.12%	11,857 $192,000
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $307,934 - $402,974	18,857 New	18,857 $340,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.